Pembrolizumab and Pemetrexed for Older Patients With Nonsquamous NSCLC and Programmed Cell Death-Ligand 1 Tumor Proportion Scores of Less Than 50% by Yoshihito Kogure, MD, PhD, Hiroya Hashimoto, PhD, Haruko Daga, MD, PhD, Yasushi Fukuda, MD, Akihiro Bessho, MD, PhD, Tadaaki Yamada, MD, PhD, Yukihiro Toi, MD, Tomoki Kimura, MD, PhD, Hiroshige Yoshioka, MD, PhD, Koichi Azuma, MD, PhD, Naoki Furuya, MD, PhD, Yasutaka Fukui, MD, PhD, Akiko M. Saito, MD, PhD, Nobuyuki Yamamoto, MD, PhD, Hideo Saka, MD, Masashi Kondo, MD, PhD

Get full text

Turtle Study: A Phase 2 Study of Durvalumab Plus Carboplatin and Etoposide in Elderly Patients With Extensive-Stage SCLC (LOGiK 2003) by Hidenobu Ishii, MD, PhD, Koichi Azuma, MD, PhD, Yuta Yamanaka, MD, Hiroshige Yoshioka, MD, PhD, Yukihiro Toi, MD, Naoki Shingu, MD, Katsuhiko Naoki, MD, PhD, Masaki Okamoto, MD, PhD, Yuko Tsuchiya-Kawano, MD, PhD, Taishi Harada, MD, Hiroyuki Inoue, MD, PhD, Hiroshi Ishii, MD, PhD, Kazunori Tobino, MD, PhD, Chiho Nakashima, MD, PhD, Yoshifusa Koreeda, MD, Yasushi Hisamatsu, MD, Shinsuke Tsumura, MD, Takashi Inagaki, MD, Keiko Mizuno, MD, PhD, Takayuki Shimose, MMath, Isamu Okamoto, MD, PhD

Get full text